Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex.
|
31754215 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using genetic models, we linked the PDE4-regulated modulation of P85 activation to the oncogenic kinase SYK.<b>Conclusions:</b> These data demonstrate that roflumilast and idelalisib suppress PI3K by distinct mechanisms, explaining the basis for their synergism, and suggest that the repurposing of PDE4 inhibitors to treat BCR-dependent malignancies is warranted.<i></i>.
|
29246942 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings point to p50 involvement in colorectal cancer development, through its engagement in the protumor activation of macrophages, and identify a candidate for prognostic and target therapeutic intervention.<i>Cancer </i>.
|
29588321 |
2018 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
All class IA p110 subunits interact with p85 regulatory subunits, and mutations/deletions in different p85 regulatory subunits have been identified in both cancer and primary immunodeficiencies.
|
29616047 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The levels of NF-κB p50 and NF-κB p65 play a role in thyroid carcinoma malignancy in vivo.
|
30014762 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
American Indians (N = 636) were recruited from two different tribal populations (NP and SW) as part of a study conducted as part of the Collaborative to Improve Native Cancer Outcomes P50 project.
|
28549179 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, according to ReMARK guidelines for reporting prognostic biomarkers in cancer, it was found that a high expression of ARHGEF7 was significantly correlated with lymph node, mesenteric and distant metastasis.
|
30132516 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, our study provides a proof of concept that blocking the interaction of p110α with p85 by a peptide can serve as a new strategy to inhibit the oncogenic activity of PI3K in cancer therapy.
|
28743532 |
2017 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
American Indians (N=636) were recruited from two different tribal populations (NP in South Dakota, SW in Arizona) as part of a study carried out as part of the Collaborative to Improve Native Cancer Outcomes P50 Project.
|
28181923 |
2017 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
They were divided into cardia and non-cardia cancer in order to study a single-nucleotide polymorphism of the nuclear factor-κB signaling pathway important node molecules P50 and I kappa B encoding genes NFKB1 and NFKBIA by desorption ionization time of flight mass spectrometry analysis and by matrix-assisted laser mass spectrometry.
|
28670959 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the combination of P85 and (-)-gossypol effectively reduced clonogenic survival of A549 cells: (11 ± 5%) compared to (-)-gossypol and P85 alone (62 ± 27% and 93 ± 13%, respectively), and enhanced radiation cancer cell killing.
|
27827005 |
2017 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutation or loss of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) is emerging as a transforming factor in cancer, but the mechanism of transformation has been controversial.
|
28630349 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer in which NF-κB pathways promote biological aggressiveness.In this issue of the JCI, Lesina et al. investigated the role of RelA, the p65 partner of p50 that together form the most common NF-κB complex, in the early stages of pancreatic malignant transformation and in established PDAC.
|
27454293 |
2016 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our studies illustrated that EriB induces cancer cell apoptosis through interfering with the binding between NF-κB and the response elements by targeting the cysteine 62 of p50, which highlights its potential for the development of p50 targeted cancer therapeutic agents.
|
25404639 |
2014 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
|
23270540 |
2012 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting interaction between C/EBPalpha basic region and NF-kappaB p50 may contribute to the therapy of AML and other malignancies expressing C/EBPs.
|
16254192 |
2005 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
|
16131837 |
2005 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By Western blot analysis, p50 and RelA were detectable mainly in the cytosolic and nuclear extracts in normal and cancer tissues, respectively, and cytosolic IkappaB-alpha expression was detectable in normal but not in cancer cervical tissues.
|
12527907 |
2003 |